GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rayont Inc (OTCPK:RAYT) » Definitions » Cash And Cash Equivalents

Rayont (Rayont) Cash And Cash Equivalents : $0.04 Mil (As of Mar. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Rayont Cash And Cash Equivalents?

Rayont's quarterly cash and cash equivalents declined from Sep. 2022 ($0.03 Mil) to Dec. 2022 ($0.01 Mil) but then increased from Dec. 2022 ($0.01 Mil) to Mar. 2023 ($0.04 Mil).

Rayont's annual cash and cash equivalents increased from Sep. 2019 ($0.00 Mil) to Sep. 2020 ($0.20 Mil) but then declined from Sep. 2020 ($0.20 Mil) to Jun. 2022 ($0.19 Mil).

Rayont Cash And Cash Equivalents Historical Data

The historical data trend for Rayont's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rayont Cash And Cash Equivalents Chart

Rayont Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Jun22
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 - - 0.20 0.19

Rayont Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.19 0.03 0.01 0.04

Rayont Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Rayont  (OTCPK:RAYT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Rayont Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Rayont's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Rayont (Rayont) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rayont Inc (OTCPK:RAYT) » Definitions » Cash And Cash Equivalents
Comparable Companies
SHRG NXMH SMFL GLUC RTON RIBT BDPT NGTF MTTCF BSFC XSWX:NESN KHC GIS XPAR:BN SHSE:603288 NSE:NESTLEIND SZSE:300999 SHSE:600887 TSE:2802 LSE:ABF
Traded in Other Exchanges
N/A
Address
228 Hamilton Avenue, 3rd Floor, Palo Alto, CA, USA, 94301
Website
https://www.rayont.com
Rayont Inc is a clinical-stage life sciences company that holds the license for registering and commercializing Photosoft technology for the treatment of all cancers. This technology is an improved next-generation Photodynamic Therapy (PDT) that uses non-toxic photosensitizers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumors, and stimulates the immune system. It has been licensed in Australia, New Zealand, China, Malaysia, and Sub-Sahara Africa. It has generated revenue from digital learning solutions provided by Rayont Technologies.
Executives
Meng Leong Liew director 1313 N. GRAND AVE. #16, WALNUT CA 91789
Kha Foo Chin director, 10 percent owner, officer: President, Treasurer ROOM 1217 NORTH TOWER, CONORDIA PLAZA, NO 1 SCIENCE MUSEUM RD., TSIM SHA TSUI E, KOWLOON K3 NA